Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Carcinotech Raises $5.3M to Develop 3D-Printed Micro-Tumors - Medical Product Outsourcing

What are you searching for?

Sign in
Financial & Business, OEM News

Carcinotech Raises $5.3M to Develop 3D-Printed Micro-Tumors

Carcino3D technology allows manufacture of 3D-printed micro-tumors using cells from patient biopsies and blood samples.

Author Image

By: Sam Brusco

Associate Editor

Scottish startup company Carcinotech has raised $5.3 million in funding to build on traction in the UK and Europe. The company said it plans to expand in the U.S. later this year.
 
The company’s Carcino3D technology allows manufacture of 3D-printed micro-tumors using cells derived from patient biopsies and blood samples. This offers precise simulation of the tumor microenvironment, which Carcinotech hopes will accelerate ethical drug screening and deliver more effective cancer treatments.
 
In October, the company began a collaboration with CELLINK to leverage bioprinting solutions and Carcinotech’s expertise to produce living, bioprinted tumors for cutting-edge cancer models.
 
Carcinotech founder and CEO Ishani Malhotra said the company’s vision is to be at the helm of cancer drug testing and offer personalized medicine testing “…to every individual suffering from cancer to improve their treatment and chance of survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians, Carcinotech aims to significantly accelerate oncology drug development.”
 
“As part of ongoing commercialization, we have built strong industry partnerships in Europe, and are now actively engaged in replicating these in North America,” Malhotra added.
 
The company also fortified its board. Its chairman is industry veteran Albert Nicholl, who chairs the board at several life sciences companies and served at Stryker and Orthofix over the course of his career. Carcinotech also launched a scientific advisory board last year with renowned leaders in oncology.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Add Medical Product Outsourcing as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics